First experiences with < sup > 177 < /sup > Lu-PSMA-617 therapy for recurrent or metastatic salivary gland cancer

CONCLUSIONS: Palliative 177Lu-PSMA therapy for salivary gland cancer may lead to rapid relief of tumour-associated discomfort and may even induce disease stabilization. It is safe, relatively well tolerated and can be considered when regular treatment options fail.PMID:34905121 | DOI:10.1186/s13550-021-00866-8

Source: Cell Research - December 14, 2021 Category: Cytology Authors: Thomas J W Klein Nulent Robert J J van Es Stefan M Willems Arthur J A T Braat Lot A Devriese Remco de Bree Bart de Keizer Source Type: research